Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunerka, Paweł, Gala, Kamila, Banach, Martyna, Dominowski, Jakub, Hucz-Kalitowska, Joanna, Mulewski, Krzysztof, Hajnal, Agnes, Mikus, Endre G., Smuga, Damian, Zagozda, Marcin, Dubiel, Krzysztof, Pieczykolan, Jerzy, Zygmunt, Beata M., Wieczorek, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377474/
https://www.ncbi.nlm.nih.gov/pubmed/32702053
http://dx.doi.org/10.1371/journal.pone.0236159
Descripción
Sumario:Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.

Ejemplares similares